Study of High-Dose Pulse Administration DN-101 (Calcitriol) in Patients With Myelodysplastic Syndrome (MDS)

Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

NCT03805581 ·Status: COMPLETED ·Phase: PHASE2

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

NCT00050843 ·Status: COMPLETED ·Phase: PHASE3

Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease

NCT02225132 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Study to Determine the Maximum Tolerated Dose, Safety and Effectiveness of Pomalidomide for Patients With Sickle Cell Disease

NCT01522547 ·Status: COMPLETED ·Phase: PHASE1

Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia

NCT01338337 ·Status: COMPLETED ·Phase: PHASE2

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

NCT00110617 ·Status: COMPLETED ·Phase: PHASE2

Research Study Investigating How Well NDec Works in People With Sickle Cell Disease

NCT05405114 ·Status: COMPLETED ·Phase: PHASE2

Decitabine for High-Risk Sickle Cell Disease

NCT01375608 ·Status: COMPLETED ·Phase: PHASE2

Repeat Peripheral Blood Stem Cell Transplantation for Patients With Sickle Cell Disease and Falling Donor Myeloid Chimerism Levels

NCT04008368 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subjects With Stable Sickle Cell Disease

NCT01597401 ·Status: COMPLETED ·Phase: PHASE1

HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity

NCT02435901 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

HLA Haploidentical Bone Marrow Transplant in Patients With Severe Sickle Cell Disease

NCT03240731 ·Status: COMPLETED ·Phase: PHASE2

Effect of Deferiprone on Oxidative-Stress and Iron-Overload in Low Risk Transfusion-Dependent MDS Patients

NCT02477631 ·Status: COMPLETED ·Phase: PHASE2

Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease

NCT01987908 ·Status: TERMINATED ·Phase: PHASE2

Rejuvesol® Washed RBC in Sickle Cell Patients Requiring Frequent Transfusions

NCT02731157 ·Status: COMPLETED ·Phase: PHASE4

Clinical Study of BRL-101 in the Treatment of Sickle Cell Disease

NCT06287099 ·Status: NOT_YET_RECRUITING ·Phase: NA

Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD)

NCT01783691 ·Status: COMPLETED ·Phase: PHASE1

Safety of ICL670 vs. Deferoxamine in Sickle Cell Disease Patients With Iron Overload Due to Blood Transfusions

NCT00067080 ·Status: COMPLETED ·Phase: PHASE2

US Phase I Study of ECT-001-CB in Patients With Sickle-Cell Disease

NCT04594031 ·Status: WITHDRAWN ·Phase: PHASE1

A Study to Test How Either a Capsule or a Tablet With NDec (Decitabine and Tetrahydrouridine) Works in the Body of Healthy People

NCT06291285 ·Status: COMPLETED ·Phase: PHASE1

Pilot Phase I/II Study of Amino Acid Leucine in Treatment of Patients With Transfusion-Dependent Diamond Blackfan Anemia

NCT01362595 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)

NCT03285178 ·Status: COMPLETED ·Phase: PHASE2

Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease

NCT00842088 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Clinical Study on the Safety and Efficacy of BRL-101 in the Treatment of Sickle Cell Disease

NCT06287086 ·Status: NOT_YET_RECRUITING ·Phase: NA

Hydroxyurea in the Treatment of Sickle Cell Disease

NCT02709681 ·Status: COMPLETED